The agreement gives Lilly access to proprietary technology that allows for the design of specially engineered enzymes aimed at correcting certain gene mutations linked to hearing loss. These enzymes, known as programmable recombinases, are built to make large, precise changes to DNA at specific locations. The approach does not rely on the cell's own DNA repair pathway, which is a key distinction. Lilly will oversee the program from early preclinical work through to commercialization. The $1.12 billion figur ...

Given how digitized the world has become, there aren't too many investors still buying gold bars and burying them in their backyard. However, gold has once again become a popular investment, and it has been on a tear in recent years. Naturally, the financial engineers on Wall Street have developed several ways to buy it online. An increasingly popular way to purchase the commodity is through tokenized gold or stablecoins. Where to invest $1,000 right now? Our analyst team just revealed what they believe ...

Core Insights - Exxon Mobil Corporation (NYSE:XOM) is recognized as one of the 12 best long-term stocks to buy [1] Group 1: Valuation and Market Position - BofA raised Exxon's price target to $135 from $129 while maintaining a Neutral rating, indicating a focus on relative valuation among US and European integrated oil companies [2] - BofA prefers Buy-rated TotalEnergies and Chevron over Neutral-rated Exxon and Shell, and Underperform-rated BP, based on relative valuations within the supermajors [2] Group 2: Strategic Partnerships - Exxon Mobil and China's BYD have signed a long-term strategic Memorandum of Understanding to expand their partnership in hybrid vehicle technology, focusing on customized product R&D and new materials [3] - The collaboration follows the launch of a specialized engine oil for BYD's plug-in electric vehicles, indicating a commitment to innovation in the automotive sector [3] Group 3: Company Overview - Exxon Mobil is one of the largest integrated energy companies globally, involved in oil and natural gas exploration, production, refining, and manufacturing of fuels, petrochemicals, lubricants, and advanced plastics [4] - The company is also investing in lower-emission initiatives, including carbon capture and lithium production, reflecting a focus on sustainability [4]

Core Viewpoint - Regeneron (REGN) reported Q4 2025 results that slightly exceeded market consensus, with no major surprises noted in the earnings report [2]. Financial Performance - The company provided expense guidance for 2026, indicating a focus on managing costs while maintaining growth [2]. Product Updates - Regeneron pre-announced Eylea, which is a significant product for the company, although specific details were not disclosed in the report [2].

GameStop Corp. (NYSE:GME) CEO Ryan Cohen unveiled his ambitious plan to transform the company into a $100 billion-plus giant. The CEO, in an interview with The Wall Street Journal on Thursday, stated that he plans to transform GameStop from an $11 billion company into a $100 billion-plus business that goes far beyond selling video games and collectibles. To achieve the same, he is considering a significant acquisition of a publicly traded company, potentially in the consumer or retail sector, where he ha ...

Core Viewpoint - AbbVie Inc. is recognized as one of the 12 best long-term stocks to buy, despite facing some challenges in clinical trials [1]. Group 1: Market Analysis - Citi has adjusted its price target for AbbVie to $230 from $235 while maintaining a Neutral rating, indicating a more supportive backdrop for the biopharma sector in 2026 due to manageable earnings expectations and reduced policy-related risks [2]. - The overall sentiment in the biopharma space suggests that earnings may exceed previous fears, contributing to a more favorable investment environment [2]. Group 2: Clinical Developments - AbbVie and Genmab's blood cancer drug, epcoritamab, did not demonstrate a statistically significant survival benefit in a late-stage study involving 483 patients with relapsed or refractory diffuse large B-cell lymphoma [3]. - Despite the lack of clear survival benefits, the study revealed positive outcomes, such as a higher number of patients achieving undetectable cancer levels, longer response durations, and improved time before requiring further treatment [4]. - Epcoritamab is already approved in several countries for other lymphoma indications, marketed as Epkinly in the U.S. and Japan, and as Tepkinly in the European Union [5].

Materials suppliers Entegris and Qnity aren't household names, but they benefit from both the AI frenzy and a broader chip-sector recovery. ...

In the age of cloud computing, it's easy to forget that IBM (NYSE: IBM) still sells its hulking mainframe systems. Following IBM's fourth-quarter earnings report, it's clear that the mainframe business is not only surviving but also thriving. Here's an incredible fact IBM CFO Jim Kavanaugh disclosed during the earnings call: IBM's mainframe business recorded its best fourth quarter revenue in more than 20 years. Revenue soared 61% year over year, adjusted for currency, driving a 17% increase in the infras ...

I have owned Apple (NASDAQ: AAPL) for many years. The tech titan has grown into my top holding. While my Apple position is only 4% of my total investment portfolio, it's a whopping 27% of my ROTH IRA. I'd like to lower my exposure in that account. However, instead of selling some of my Apple stock, I'm using it to make passive income through a unique strategy. Here's a look at my trade and how you can more easily mimic this income strategy through a passive investment in an exchange-traded fund (ETF). Whe ...

Group 1 - BofA has lowered the price target on Peloton (PTON) to $9 from $11 while maintaining a Buy rating ahead of the fiscal Q2 results report on February 5 [1] - The firm remains optimistic about Peloton's product-led strategy, AI integration, and expanding ecosystem [1] - The reduction in price target is attributed to expectations of higher churn following the price increases implemented in October [1]